EcoDrugPlus

Checkpoint Kinase 1

Ensembl ID : ENSBMSG00010011794
Gene Symbol: CHEK1
1 Cross references
179 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSBMSG00010013536
Gene Symbol: CHEK2
1 Cross references
206 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSBMSG00010001131
Gene Symbol: CCKAR
1 Cross references
201 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSBMSG00010021785
Gene Symbol: CCKBR
1 Cross references
270 Possible Orthologues:

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSBMSG00010008857
Gene Symbol: CHRM1
1 Cross references
104 Possible Orthologues:

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSBMSG00010018848
Gene Symbol: CHRM2
1 Cross references
261 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSBMSG00010015469
Gene Symbol: CHRM3
1 Cross references
257 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSBMSG00010015622
Gene Symbol: CHRM4
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSBMSG00010013851
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSBMSG00010010697
Gene Symbol: CHRNA4
1 Cross references
206 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 7 Subunit

Ensembl ID : ENSBMSG00010008603
Gene Symbol: CHRNA7
1 Cross references
249 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSBMSG00010001445
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).